The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

BACKGROUND: The anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of non-small cell lung cancer (NSCLC), but not all PD-1/PD-L1 positive patients can get benefit from it. Compensatory expression of other immune checkpoints may be...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yayi, Liu, Sangtian, Mattei, Jane, Bunn, Paul A, Zhou, Caicun, Chan, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923225/
https://www.ncbi.nlm.nih.gov/pubmed/29731605
http://dx.doi.org/10.2147/DDDT.S163304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923225/
https://www.ncbi.nlm.nih.gov/pubmed/29731605
http://dx.doi.org/10.2147/DDDT.S163304

Ejemplares similares